Showing results (241-250 of 390) with videos related to
Sort By:
Pageof 39
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 9, 2024
Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MSMarcus W Koch, Carlos Camara-Lemarroy, Eva Strijbis, et al.BMC Neurology|October 10, 2024
Middle-range scores from the patient determined disease steps scale reflect varying levels of walking dysfunction in multiple sclerosisRobert Motl, Whitney Neal, Deborah Backus, et al.JAMA Network Open|April 13, 2026
Economic Evaluation of Thymectomy for the Treatment of Nonthymomatous Myasthenia GravisJoseph Lord, Matthew Walton, Peter Murphy, et al.Annals of Clinical and Translational Neurology|May 4, 2021
Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disabilityMatthew R Brier, Abraham Z Snyder, Aaron Tanenbaum, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 12, 2023
Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosisEva M Strijbis, Eline Coerver, Jop Mostert, et al.Multiple Sclerosis and Related Disorders|May 27, 2015
Risk tolerance to MS therapies: Survey results from the NARCOMS registryRobert J Fox, Amber Salter, Joan M Alster, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.Neurology|February 29, 2020
Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United StatesAhmed Z Obeidat, Yasir N Jassam, Le H Hua, et al.BMJ Neurology Open|June 3, 2021
Acute flaccid myelitis: long-term outcomes recorded in the CAPTURE study compared with paediatric transverse myelitisBenjamin Greenberg, Patricia Plumb, Gary Cutter, et al.Pediatrics|October 21, 2009
Clinical and economic effects of iNO in premature newborns with respiratory failure at 1 yearR Scott Watson, Gilles Clermont, John P Kinsella, et al.Pageof 39